Plus Therapeutics (PSTV) shares jumped nearly 183% in recent trading Thursday after the company said the US Food and Drug Administration conditionally accepted the proprietary name for its lead tumor therapy candidate.
The medicine will be known as Reyobiq and will be subject to a proprietary name review once a new drug application is submitted, Plus Therapeutics said.
The company is developing Reyobiq as an injectable radiotherapy to treat central nervous system tumors.
Price: 1.45, Change: +0.93, Percent Change: +182.78
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。